This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bet on Biotech's Grand Prize

Biotech investors like to dream big. And right now, there's no bigger dream than owning stock in the first company to develop a truly effective drug against Alzheimer's disease.

A new drug for Alzheimer's -- one that can stop or even reverse the insidious mind-destroying course of the disease -- is the biggest unclaimed prize in biotech. Such a drug will generate billions of dollars in sales for the company that develops it.

As for the investors in that company, well, need I say more?

The numbers tell the story: Between 4 million and 5 million people in the U.S. are diagnosed with Alzheimer's, a figure that could triple by the middle of this century as baby boomers (and the rest of us) age and live longer.

Many baby boomers are now spending a fortune caring for parents with Alzheimer's. Tomorrow, the boomers themselves will be facing the tragedy of the disease, and their kids will bear the costs -- which are enormous. The Alzheimer's Association estimates direct and indirect costs of the disease now amount to more than $148 billion.

Aricept, the leading Alzheimer's drug today, generates about $1 billion in sales for its owners Esai and Pfizer (PFE - Get Report). But it's only minimally effective. At best, it slows the rate at which Alzheimer's destroys the ability to think, to remember, to take care of one's self.

To watch Janet Alvarez's video take of this column, click here .
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
COR $76.54 -1.30%
MDVN $59.06 2.68%
LLY $74.89 -1.80%
MYGN $33.95 -6.20%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs